Cart is empty
View Cart
Subtotal: $0.00
JOIN NOW!
Featured Image

Welcome New Members November 2021!

  • Posted by ISPE Boston
  • On December 2, 2021
We would like to introduce the Members who joined ISPE in November 2021, welcome them to the Chapter and encourage them (and all our members) to take advantage of the many professional development, networking and information resources available through ISPE. Fellow ISPE members are a terrific resource for help with everyday professional challenges. And the […]
Read More
 1
 Featured Image

Chapter Member Anniversaries: December 2021

  • Posted by ISPE Boston
  • On December 2, 2021
Please congratulate the following members celebrating milestone anniversaries in December 2021.  Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Twenty Years Marc W. Abromovitz, CIH Novartis Pharmaceuticals Judith R. Bodette, Thermo Fisher VVS Jack G. Campion, P.E., The Hart Companies Carl J. Carlson, Exyte Thomas R. Choyce, PE, Biogen […]
Read More
 
 Featured Image

Pfizer Seeks EUA for COVID-19 Antiviral Pill

  • Posted by ISPE Boston
  • On November 18, 2021
Pfizer is seeking Emergency Use Authorization (EUA) of its investigational oral antiviral candidate, Paxlovid (PF-07321332; ritonavir), for the treatment of mild to moderate COVID-19 in patients at increased risk of hospitalizations or death. If authorized or approved, Paxlovid would be the first oral antiviral of its kind, a 3CL protease inhibitor specifically designed to combat […]
Read More
 1
 Featured Image

Moderna in Deal with Metagenomi on Gene Editing Therapeutics

  • Posted by ISPE Boston
  • On November 18, 2021
Moderna and Metagenomi, have entered into a strategic R&D collaboration focused on advancing new gene editing systems for in vivo human therapeutic applications. The collaboration will utilize Metagenomi’s novel gene editing tools and leverage Moderna’s mRNA platform, as well as lipid nanoparticle (LNP) delivery technologies, with the goal of developing curative therapies for patients with serious genetic diseases. […]
Read More
 1
 Featured Image

Machine Learning Platform Attracts $370M for Generate Biomedicines

  • Posted by ISPE Boston
  • On November 18, 2021
Cambridge-based Generate Biomedicines has raised $370 Million in a Series B financing to advance the development of its machine learning-powered drug generation platform. The Generate platform can rapidly generate antibodies, peptides, enzymes, cell and gene therapies to meet any therapeutic need. This approach enables Generate to create previously impossible therapeutics and to do so with unprecedented speed and […]
Read More
 1
 Featured Image

First Annual Holiday Card and Gift Swap!

  • Posted by ISPE Boston
  • On November 16, 2021
Join the ISPE Boston Women in Pharma (WIP) for the First Annual Holiday Card and/or Gift Exchange. Spread a little holiday cheer, meet new people, and connect! We are offering the option of swapping cards, gifts (minimum $25 in value) or both. Great opportunity to give a little and get a whole lot in return! […]
Read More
 
 Featured Image

Product Show Committee Kicks-Off 2022 Planning with Volunteer Social

  • Posted by ISPE Boston
  • On November 15, 2021
The Product Show Committee met to kick-off planning for the 2022 Product Show on Monday, November 8th at Flight Club, a social darts venue in Boston. This first meeting was an opportunity for volunteers both new and old to meet and to go over what’s in store for the coming year. Volunteers enjoyed a variety […]
Read More
 1
 Featured Image

We Want You for the Veterans In Pharma Committee!

  • Posted by Victor Taubinger
  • On November 11, 2021
There are so many veterans within our ISPE Boston Area Chapter membership and, first off, we’d like to say thank you for your service! For those who don’t know, some of our Chapter leaders have formed a Veterans In Pharma committee. This committee hosted an initial kick-off event at the 2019 Product Show and a […]
Read More
 
 Featured Image

Flagship Pioneering to Partner with Cystic Fibrosis Foundation on CF

  • Posted by ISPE Boston
  • On November 11, 2021
Flagship Pioneering has entered into a strategic partnership with the Cystic Fibrosis Foundation and Flagship’s Pioneering Medicines to develop therapeutics for cystic fibrosis. Through this agreement, the Cystic Fibrosis Foundation has committed up to $110 million to Pioneering Medicines to bring forward multiple development candidates and develop these candidates to human proof of concept. “Despite recent advances, approximately 10% […]
Read More